U.S. Software Stock News

We'd be surprised if Granite Point Mortgage Trust Inc. ( NYSE:GPMT ) shareholders haven't noticed that the Independent...

Unfortunately for some shareholders, the WORK Medical Technology Group LTD ( NASDAQ:WOK ) share price has dived 26% in...

Jumia Technologies AG ( NYSE:JMIA ) shareholders are probably feeling a little disappointed, since its shares fell 2.6...

Whilst it may not be a huge deal, we thought it was good to see that the Medalist Diversified REIT, Inc. ( NASDAQ:MDRR...

Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have retraced a considerable 26% in the last month, reversing a fair...

Investors who take an interest in Arq, Inc. ( NASDAQ:ARQ ) should definitely note that the CEO, President & Director...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights Quantum-Si's significant retail investors ownership suggests that the key decisions are influenced by...

Innoviva, Inc. recently reported third-quarter 2025 earnings, showcasing a substantial year-over-year surge in both revenue, at US$107.8 million, and net income, at US$89.91 million, alongside the announcement of a new US$125 million share repurchase program with no set end date. This combination of robust financial performance and a significant buyback initiative highlights the company's strengthened financial position and management’s confidence in its future outlook. We'll explore how...

Plains GP Holdings, L.P. recently reported third quarter results, showing US$11.58 billion in sales and net income of US$83 million, both for the period ended September 30, 2025. Despite a decrease in sales compared to a year ago, the company's net income and earnings per share rose significantly, reflecting improved profitability. We'll explore how this higher net income, achieved even as sales declined, may influence Plains GP Holdings' long-term investment outlook. AI is about to change...

Ever wondered if LendingClub’s latest run-up means the stock is still a good deal, or if the ship has already sailed on value? Let’s take a closer look at what’s really happening beneath the surface before making that call. The stock has had quite the ride, climbing 15.5% over the past year and racking up a huge 151.3% gain over five years, even with a slight 5% pullback over the last week. Some of the excitement and volatility stems from recent headlines about fintech partnerships and...

Earlier this month, Reinsurance Group of America announced the opening of its first New York City office at Park Avenue Tower, reflecting a focus on high-quality assets and a people-first workplace in a premier Midtown Manhattan location. On the research front, RGA's recent study suggests that widespread adoption of GLP-1 medications could lower US mortality by 3.5% by 2045, underscoring potential long-term implications for population health and the insurance sector. We will examine how the...

Perella Weinberg Partners recently reported third-quarter financial results that missed analyst expectations, with revenue declining due to softer mergers and acquisitions activity. Management emphasized a record level of active client engagements and highlighted that contributions from new hires and the Devon Park acquisition are anticipated mainly in 2026. We'll examine how leadership's outlook for future pipeline growth informs the company’s broader investment narrative amid recent...

Earlier this month, Cytek Biosciences reported third-quarter 2025 earnings, showing revenue of US$52.29 million and a net loss of US$5.48 million compared to net income in the prior year, and reaffirmed its full-year revenue guidance of US$196 million to US$205 million. This combination of improved quarterly revenue but a swing to quarterly and year-to-date losses provided investors with contrasting signals about Cytek’s ongoing financial health and outlook. We’ll review how the...

Inhibrx Biosciences (INBX) shared that its Phase 2 trial for ozekibart in chondrosarcoma achieved its primary endpoint, showing a clear improvement in progression-free survival. The company now plans to move forward and submit a biologics license application to the FDA next year, an important step that reflects confidence in its trial results and future prospects. See our latest analysis for Inhibrx Biosciences. Inhibrx Biosciences’ journey over the past year reflects how powerful clinical...

Autolus Therapeutics (AUTL) just released its latest quarterly earnings and is drawing increased investor attention thanks to several key developments. The company continues to expand commercial access for Obe-cel, reports strong manufacturing results, and anticipates new data at the upcoming ASH conference. See our latest analysis for Autolus Therapeutics. Autolus Therapeutics has seen a burst of activity lately, from broadening commercial access and updating its leadership team to advancing...

Legence (LGN) shares have moved higher recently, catching investors’ attention after the company reported a strong annual net income improvement and steady revenue growth. The stock is up more than 20% over the past month. See our latest analysis for Legence. Legence’s 1-month share price return of 20.2% is grabbing attention, especially after its annual profit surge. Momentum appears to be building as confidence returns and investors increasingly factor in the company’s growth story. With...

Scorpio Tankers recently sold over 2.3 million shares in DHT Holdings, reducing its stake while still retaining 1,169,568 shares, and announced plans to expand its fleet by building two additional VLCCs in South Korea with Hanwha Ocean Co. Ltd. This shift in DHT's shareholder structure, driven by Scorpio Tankers' divestment and reinvestment in its own fleet growth, may influence market perspectives on both companies' future directions. We'll explore how Scorpio Tankers' decision to reduce...

Anavex Life Sciences (AVXL) reported that its lead drug candidate, blarcamesine, for early Alzheimer's disease faced a negative trend vote from the European Medicines Agency's CHMP. This outcome has sparked new questions about regulatory pathways and next steps for the company. See our latest analysis for Anavex Life Sciences. Anavex’s regulatory news contributed to a dramatic shift in sentiment, with the stock’s 1-day share price return tumbling 35.94% and momentum clearly fading. Despite...

Tootsie Roll Industries (TR) just posted its third quarter earnings, showing higher revenue and net income compared to last year. The latest financials offer investors a snapshot of how the company’s performance is trending in 2025. See our latest analysis for Tootsie Roll Industries. Tootsie Roll Industries’ latest results arrive as its share price has gathered impressive momentum, rallying over 24% year-to-date and delivering a total shareholder return of nearly 29% over the past year. The...

Delek US Holdings recently reported third quarter financial results, showing sales of US$2,887 million and net income of US$178 million, along with the completion of nearly US$586.1 million in share repurchases since 2018. This marks a major turnaround from a loss in the previous year and highlights the company's substantial capital allocation efforts. We’ll explore how Delek’s strong turnaround in profitability and completion of its share buyback program impact the investment...

Rezolve AI (NasdaqGM:RZLV) has welcomed a lineup of senior leaders from Apple, Google, Microsoft, SAP, and Tata Digital. This signals strong industry belief in its approach. The company is accelerating its commercial push across the US and Europe. See our latest analysis for Rezolve AI. After a flurry of executive recruits and major expansion plans, Rezolve AI’s shares have seen plenty of action. Over the past month, the company posted a sharp -45.97% share price return and is down -27.87%...

Rambus (RMBS) has recently caught the attention of investors looking for potential opportunities in the semiconductor industry. The stock’s performance over the past three months, with a 28% gain, has sparked interest in its underlying momentum. See our latest analysis for Rambus. After surging 28% over the last three months, Rambus is still building momentum, delivering a remarkable 78% share price return year-to-date. Over the past year, investors have enjoyed an even higher total...

On November 3, 2025, Sila Realty Trust's Board approved a quarterly cash dividend of US$0.40 per share payable on December 4, 2025, and reported third quarter results with US$49.85 million in revenue and US$0.21 in diluted earnings per share from continuing operations, consistent with last year. A key insight is that Sila Realty Trust continues to show modest revenue growth alongside sustained earnings, while maintaining its dividend payout. We'll explore how reaffirming a US$0.40 dividend...